Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06727799 · ClinicalTrials.gov registry record
A Non-Treatment Clinical Evaluation of the ELITA Single Piece Patient Interface for Docking Procedure With the ELITA
A clinical trial of Refractive Error, sponsored by Johnson & Johnson Surgical Vision.
- Completed
- Registry status
- 55
- Enrollment target
- 2
- Study locations
NCT06727799: Completed study of Refractive Error, sponsored by Johnson & Johnson Surgical Vision.
NCT06727799 is a study of Refractive Error that has completed, run by Johnson & Johnson Surgical Vision. The registered enrollment target is 55 participants, below the 607-participant average among 5 other Refractive Error trials with a reported enrollment target (91% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06727799, a study of Refractive Error, has completed, sponsored by Johnson & Johnson Surgical Vision.
- COMPLETED
- Registry status
- 55 participants
- Enrollment target
- 2
- Study locations
Study Summary
Open label, prospective, randomized, multicenter, measurement only feasibility study to evaluate the docking procedure using the ELITA Single Piece Patient interface in conjunction with the ELITA system
Primary Outcome
Applanation of the cornea with the Patient interface resulting meniscus formation at PI interface of at least 10 mm in diameter with continuous vacuum suction engaged and no observed eye movement upon successful vacuum engagement that allows centration of a 9 mm flap based on GUI overlay on the centration screen
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Docking Assessment / Observation
Study Locations (2)
California
- Stanford Eye Laser Center - Palo Alto
Utah
- Hoopes Vision - Draper
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2024-12-06 |
| Est. Completion | 2025-03-28 |
What the finished NCT06727799 record still lists
NCT06727799 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 55 participants, a relatively small participant target, below the 607-participant average among 5 other Refractive Error trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Refractive Error appearing as the primary indexed condition, and to 1 intervention - of which Docking Assessment / Observation is the first listed.
NCT06727799 reports a single indexed study location in California, Utah.
Frequently Asked Questions
What is clinical trial NCT06727799 about?
NCT06727799 is a clinical study titled "A Non-Treatment Clinical Evaluation of the ELITA Single Piece Patient Interface for Docking Procedure With the ELITA". Open label, prospective, randomized, multicenter, measurement only feasibility study to evaluate the docking procedure using the ELITA Single Piece Patient interface in conjunction with the ELITA system
What is the current status of trial NCT06727799?
This trial is currently completed. The enrollment target is 55 participants. The study started on 2024-12-06. Estimated completion is 2025-03-28.
What conditions does trial NCT06727799 study?
This clinical trial studies the following conditions: Refractive Error.
What interventions are being tested in trial NCT06727799?
The interventions under investigation include: Docking Assessment / Observation (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06727799?
This trial is sponsored by Johnson & Johnson Surgical Vision, which has 22 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06727799 being conducted?
This trial has 2 study locations across California, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Refractive Error
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Post Marketing Clinical Study on the Efficacy of Lenses From a New Prescription Protocol
RECRUITING · NA
-
Proof of Concept Study for First-Sight Refractive Error Correction: Direct Comparison to Manifest Refraction and Autorefraction Results
COMPLETED
-
Comparative In-Vivo Wetting Characteristics of Silicone Hydrogel Materials With Selected Lens Care Systems
COMPLETED · NA
-
A Study of Interventions to Reduce Disability From Visual Loss in Nursing Home Residents
COMPLETED · Phase 4
-
Wavefront-guided LASIK for Monovision Treatment of Myopic Subjects With Presbyopia
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI